Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial

Biology of Blood and Marrow Transplantation

Volumn 23, Issue 3, 2017, Pages 512-521

  Grimley, Michael S ^a   Chemaly, Roy F ^b   Englund, Janet A ^c   Kurtzberg, Joanne ^d   Chittick, Gregory ^e   Brundage, Thomas M ^e   Bae, Andrew ^e   Morrison, Marion E ^e   Prasad, Vinod K ^d  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Chimerix   (United States)

Author keywords

Adenoviruses; Antiviral; BCV; Brincidofovir; CMX001; Stem cell transplantation; Treatment

Indexed keywords

BRINCIDOFOVIR; CREATININE; LEFLUNOMIDE; PLACEBO; RIBAVIRIN; CYTOSINE; PHOSPHONIC ACID DERIVATIVE;

ABDOMINAL PAIN; ACUTE GRAFT VERSUS HOST DISEASE; ADENOVIRUS INFECTION; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; ASYMPTOMATIC INFECTION; BONE MARROW TOXICITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CREATININE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; HUMAN HERPESVIRUS 6; INFANT; LYMPHOCYTE COUNT; MALE; MENINGITIS; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCAL PNEUMONIA; TREATMENT DURATION; VIREMIA; VIRUS LOAD; AGED; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; NEWBORN; PREMEDICATION; PRESCHOOL CHILD; SURVIVAL ANALYSIS; TREATMENT FAILURE; YOUNG ADULT;

ADENOVIRIDAE INFECTIONS; ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CYTOSINE; DIARRHEA; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PREMEDICATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE; VIREMIA; YOUNG ADULT;

EID: 85009395395     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2016.12.621     Document Type: Article

References (35)

1. 1 Baldwin, A., Kingman, H., Darville, M., et al. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant 26 (2000), 1333–1338.
2. 2 Claas, E.C., Schilham, M.W., de Brouwer, C.S., et al. Internally controlled real-time PCR monitoring of adenovirus DNA load in serum or plasma of transplant recipients. J Clin Microbiol 43 (2005), 1738–1744.
3. 3 Lion, T., Baumgartinger, R., Watzinger, F., et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 102 (2003), 1114–1120.
4. 4 Shields, A.F., Hackman, R.C., Fife, K.H., Corey, L., Meyers, J.D., Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med 312 (1985), 529–533.
5. 5 La Rosa, A.M., Champlin, R.E., Mirza, N., et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 32 (2001), 871–876.
6. 6 van Tol, M.J., Kroes, A.C., Schinkel, J., et al. Adenovirus infection in paediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery. Bone Marrow Transplant 36 (2005), 39–50.
7. 7 Flomenberg, P., Babbitt, J., Drobyski, W.R., et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 169 (1994), 775–781.
8. 8 Howard, D.S., Phillips, I.I.G.L., Reece, D.E., et al. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 29 (1999), 1494–1501.
9. 9 Hoffman, J.A., Shah, A.J., Ross, L.A., Kapoor, N., Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7 (2001), 388–394.
10. 10 Yusuf, U., Hale, G.A., Carr, J., et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation 81 (2006), 1398–1404.
11. 11 Sandkovsky, U., Vargas, L., Florescu, D.F., Adenovirus: current epidemiology and emerging approaches to prevention and treatment. Curr Infect Dis Rep, 16, 2014, 416.
12. 12 Ison, M.G., Adenovirus infections in transplant recipients. Clin Infect Dis 43 (2006), 331–339.
13. 13 Williams, K.M., Agwu, A.L., Dabb, A.A., et al. A clinical algorithm identifies high risk pediatric oncology and bone marrow transplant patients likely to benefit from treatment of adenoviral infection. J Pediatr Hematol Oncol 31 (2009), 825–831.
14. 14 Yilmaz, M., Chemaly, R.F., Han, X.Y., et al. Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant 48 (2013), 1218–1223.
15. 15 Legrand, F., Berrebi, D., Houhou, N., et al. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant 27 (2001), 621–626.
16. 16 Muller, W.J., Levin, M.J., Shin, Y.K., et al. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis 41 (2005), 1812–1816.
17. 17 Neofytos, D., Ojha, A., Mookerjee, B., et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 13 (2007), 74–81.
18. 18 Ljungman, P., Treatment of adenovirus infections in the immunocompromised host. Eur J Clin Microbiol Infect Dis 23 (2004), 583–588.
19. 19 Toth, K., Spencer, J.F., Dhar, D., et al. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci USA 105 (2008), 7293–7297.
20. 20 Florescu, D.F., Pergam, S.A., Neely, M.N., et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant 18 (2012), 731–738.
21. 21 Grimley, M., Papanicolaou, G., Prasad, V.K., et al. CMX001 is a potential treatment for adenovirus infection: preliminary antiviral activity results from an open-label, expanded access study of CMX001 for the treatment of serious or life-threatening diseases caused by double-stranded DNA viruses [abstract]. Bone Marrow Transplant, 48, 2014, S56.
22. 22 Marty, F.M., Winston, D.J., Rowley, S.D., et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 369 (2013), 1227–1236.
23. 23 Ebner, K., Pinsker, W., Lion, T., Comparative sequence analysis of the hexon gene in the entire spectrum of human adenovirus serotypes: phylogenetic, taxonomic, and clinical implications. J Virol 79 (2005), 12635–12642.
24. 24 Kuo, D.H., Simmons, F., Xagoraraki I. A new set of PCR assays for the identification of multiple human adenovirus species in environmental samples. J Appl Microbiol 107 (2009), 1219–1229.
25. 25 Lu, X., Erdman, D.D., Molecular typing of human adenoviruses by PCR and sequencing of a partial region of the hexon gene. Arch Virol 151 (2006), 1587–1602.
26. 26 Papadimitriou, J.C., Cangro, C.B., Lustberg, A., et al. Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. Int J Surg Pathol 11 (2003), 295–302.
27. 27 Welch, D.C., Wirth, P.S., Goldenring, J.R., Ness, E., Jagasia, M., Washington, K., Gastric graft-versus-host disease revisited: does proton pump inhibitor therapy affect endoscopic gastric biopsy interpretation?. Am J Surg Pathol 30 (2006), 444–449.
28. 28 Marty, F.M., Winston, D.J., Chemaly, R.F., et al. Brincidofovir for cytomegalovirus (CMV) prophylaxis after allogeneic hematopoietic cell transplantation (HCT) in CMV-seropositive recipients: a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial [abstract]. Biol Blood Marrow Transplant, 22, 2016, S23.
29. 29 Detweiler, C.J., Sung, A.D., Saullo, J.L., et al. Brindcidofovir (CMX001) toxicity: another potential mimicker of gastrointestinal graft versus host disease [abstract]. Mod Pathol, 29(S2), 2016, 169A.
30. 30 Gilead, Vistide (cidofovir injection) prescribing information. Available from: http://www.gilead.com/~/media/files/pdfs/medicines/other/vistide/vistide.pdf, 2000 Accessed on August 19, 2015.
31. 31 Painter, W., Robertson, A., Trost, L.C., Godkin, S., Lampert, B., Painter, G., First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother 56 (2012), 2726–2734.
32. 32 Ciesla, S.L., Trahan, J., Wan, W.B., et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 59 (2003), 163–171.
33. 33 Morrison, M., Avery, R., Kwak, E., Brundage, T., Mommeja-Marin, H., Switch from existing antivirals to brincidofovir leads to improving renal function [abstract]. Transplantation, 98, 2014, 106.
34. 34 Tippin, T.K., Morrison, M.E., Brundage, T.M., Mommeja-Marin, H., Brincidofovir is not a substrate for the human organic anion transporter 1 (OAT1): a mechanistic explanation for the lack of nephrotoxicity observed in clinical studies. Ther Drug Monit 38 (2016), 777–786.
35. 35 Lion, T., Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev 27 (2014), 441–462.